Clinical Trials Browser

Peripheral Nervous System Diseases × pembrolizumab × 90 days × Clear all

NCT07629700 2026-06-05

ENDEAVOR

Phase NA Not yet recruiting

Carcinoma, Transitional Cell, Peripheral Nervous System Diseases

NCT07484022 2026-06-03

Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer

Phase 1 Recruiting

Carcinoma, Transitional Cell, Peripheral Nervous System Diseases